Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a non » _ non (Expand Search)
-
201
-
202
<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling.
Published 2017“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”
-
203
-
204
-
205
Image_5_miR-144-5p and miR-451a Inhibit the Growth of Cholangiocarcinoma Cells Through Decreasing the Expression of ST8SIA4.tif
Published 2021“…This study aimed to investigate the action mechanism of miR-144-5p and miR-451a in cholangiocarcinoma. We found that miR-144-5p and miR-451a were significantly decreased in cholangiocarcinoma patient samples compared to the adjacent normal bile duct samples. …”
-
206
Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice
Published 2011“…All bladders were voided of urine prior to weighing. Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and Ha-transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. , Male belinostat-treated mice (n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg average weight). , Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in bladder weight versus control (n = 6, 53.3 mg average weight).…”
-
207
-
208
-
209
mGluR5 receptor decreased glycinergic currents.
Published 2019“…<p>(<b>A–B</b>) Bath perfusion of DHPG for 3 min reduced GlyR-IPSCs (<b>A</b>; 70.2 ± 4.2% of baseline at 15–20 min post-DHPG, <i>t</i>[16] = 6.707, <i>p</i> < 0.001, paired Student <i>t</i> test), but not GABA<sub>A</sub>-receptor–mediated IPSCs (<b>B</b>; 102.9 ± 3.3% of baseline at 15–20 min post-DHPG, <i>t</i>[5] = 0.347, <i>p</i> = 0.743) in spinal slices of mice. …”
-
210
-
211
-
212
-
213
-
214
Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>.
Published 2015“…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
-
215
Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx
Published 2022“…After adjusting for other confounders, the waiting time was identified as an independent prognostic factor.</p>Conclusions<p>A long waiting time before treatment may decrease the survival of stage IA1 NSCLC patients. …”
-
216
-
217
Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability.
Published 2015“…<b>a. RT-qPCR analysis:</b> relative TMPRSS2-ERG fusion variants III and IV mRNA levels were analysed and compared to non-treated cells. …”
-
218
-
219
-
220
Proteasome activity was decreased in the <i>myc-rpt6-S119A</i> mutant.
Published 2017“…<p>(A) Lysates from strains in stationary phase (A<sub>600</sub>>5.0) were subjected to native gel electrophoresis followed by an in-gel activity assay with the fluorogenic proteasome substrate Suc-LLVY-AMC. …”